Recent news on Raptiva

XOMA Reports First Quarter 2007 Results  -  May 11, 2007
PharmaLive.com (press release),US sales of RAPTIVA(r) in the first quarter of 2007 were $23.8 million. US sales in the first quarter of 2006 were $21.4 million.

XOMA Executives to Present at BIO2007 Convention, Rodman & Renshaw ...  -  May 8, 2007
PharmaLive.com (press release),XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Merck Serono SA) to treat

2007 BIO International Convention Exhibitor Profiles Continued, M ...  -  May 3, 2007
Genetic Engineering News (press release),XOMA receives royalties for RAPTIVA(R) and LUCENTIS(R). Other strategic collaborations include Novartis International AG (formerly Chiron Corporation),

XOMA Announces Clinical Trial Plans for XOMA 052 in Type 2 Diabetes  -  Apr 12, 2007
PipelineReview.com (press release),XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Merck Serono SA) to treat

Genentech Q1 2007 Earnings Call Transcript  -  Apr 11, 2007
Seeking Alpha,Completing immunology, US sales of Raptiva were $24 million in the quarter, a 14% increase over the prior year. Now with regard to our tissue growth and

Genentech Announces First Quarter 2007 Results  -  Apr 11, 2007
Genetic Engineering News (press release),Pulmozyme(R) 52 49 6 --------------------------------------- --------- --------- ---------- Raptiva(R) 24 21 14

Merck Serono SA to Voluntarily Delist and Deregister its Bearer ...  -  Apr 6, 2007
Drug Newswire (press release),The Company has recently entered the psoriasis area with Raptiva(R). Merck Serono's research programs are focused on growing these businesses and on

EPG Patient Direct Partners With Merck Serono To Produce Psoriasis ...  -  Mar 29, 2007
Medical News Today (press release),Neurology (Rebif®), CardioMetabolic Care (Glucophage®, Concor®), Reproductive Health (Gonal-f®), Dermatology (Raptiva®) and other therapeutic areas.

XOMA Reports 2006 Results  -  Mar 8, 2007
Primenewswire (press release),In early February, Genentech released positive statistically significant safety and efficacy results of a 12-week Phase IV study of RAPTIVA(r) in psoriasis

Merck KGaA Announces Serono Preliminary Figures for 2006  -  Mar 23, 2007
Drug Newswire (press release),Sales of Raptiva(R) more than doubled to $70 million in 2006 and increased by 84% during the fourth quarter compared to the prior year.

Merck KGaA is delighted as Serono earnings soar  -  Mar 1, 2007
Pharma Times (subscription),...competition in the market for MS drugs, while revenues from Raptiva (efalizumab), Serono's psoriasis drug, more than doubled to $70 million in 2006.

High hopes for burn scar laser treatment  -  Mar 7, 2007
Daily News - Galveston County,Studies by Brent Kelly on the use of Raptiva in patients who have failed treatment with other injected psoriasis drugs as well as a 5-year safety study of

Merck Serono Confirms Previously Announced 2006 Figures  -  Mar 21, 2007
PharmaLive.com (press release),The Company has recently entered the psoriasis area with Raptiva(R). Merck Serono's research programs are focused on growing these businesses and on

The Dermatology Market: Identifying High Growth Brands, Future ...  -  Mar 13, 2007
PharmaLive.com (press release),The psoriasis market is forecast to post the most aggressive growth rates over the period to 2011, as Raptiva and Daivobet drive growth over the forecast

XOMA Announces Automatic Conversion of All Remaining Outstanding ...  -  Mar 7, 2007
PharmaLive.com (press release),XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Merck Serono SA) to treat

XOMA Announces Planned Retirement of Chief Executive Officer  -  Feb 26, 2007
PharmaLive.com (press release),XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Merck-Serono,

Genentech Announces Positive Results from a Phase IV Study of ...  -  Feb 9, 2007
Drug Newswire (press release),The primary endpoint of this study was to evaluate the efficacy of Raptiva, defined as the attainment of a Physician's Global Assessment (PGA) rating of

Genentech Announces Positive Results from a Phase IV Study of ...  -  Feb 2, 2007
PR Newswire (press release),..."These data support Raptiva as an effective treatment option for this patient population." Study Design and Key Findings The primary endpoint of this study

AAD: Raptiva Helps in Psoriasis of Hands and Feet  -  Feb 2, 2007
MedPage Today,2 -- A 12-week course of Raptiva (efalizumab) significantly improved chronic severe plaque psoriasis of the hands and feet, researchers here reported today.

Biologic Drug Raptiva Effective in Treating Psoriasis of Hands and ...  -  Feb 2, 2007
Biologic Drug Report,Raptiva is a humanized therapeutic antibody initially approved by the FDA in 2003 that is designed to selectively and reversibly block the activation,

Genentech (DNA) Announced Results from a Phase IV Study of Raptiva  -  Feb 2, 2007
StreetInsider.com (subscription),Genentech, Inc. (NYSE: DNA) announced results from a Phase IV study of Raptiva (efalizumab) that showed statistically significant improvement in patients

It’s Alive! Meet One of Biotech’s Zombies  -  Feb 12, 2007
Wilmington Morning Star,It did help develop Genentech’s psoriasis drug, Raptiva, in exchange for a cut of any profits the product generated. But Raptiva, approved in 2003,

Dear Subscriber to TheStreet.com Stocks Under $10,  -  Feb 6, 2007
TheStreet.com (subscription),Currently, Xoma's most significant royalty stream comes from Raptiva, a treatment for plaque psoriasis that is marketed in the US by biotech behemoth

Market Report -- In Play (DNA)  -  Feb 2, 2007
MSN MoneyGenentech announces "positive results" from a Phase IV study of Raptiva in patients with moderate-to-severe hand and foot psoriasis Co announced results

Zacks Analyst Blog Highlights: Xoma, Ltd., Genentech, AstraZeneca ...  -  Feb 7, 2007
Business Wire (press release),Genentech (NYSE: DNA) and UCB Pharma reported positive psoriasis data on Raptiva and Cimzia, respectively, at the American Academy of Dermatology (ADA)

New psoriasis treatmentsmay help when others fail  -  Feb 5, 2007
SouthCoastToday.com,Three such drugs are Raptiva, Humira and Enbrel. They are self-administered injections used in the manner diabetics use insulin, but they are not lifelong

Survey: Most Moderate to Severe Psoriasis Patients Do Not Receive ...  -  Feb 2, 2007
Biologic Drug Report,Biologics such as Enbrel, Remicade, Raptiva, or Amevive are the leading biologic drugs used to treat psoriasis.

PDL BioPharma Announces Fourth Quarter and Full Year 2006 ...  -  Feb 21, 2007
Yahoo! News (press release)Herceptin, Avastin, Lucentis and Raptiva are registered US trademarks of Genentech, Inc. Xolair is a registered trademark of Novartis AG.

PDL BioPharma Announces Fourth Quarter and Full Year 2006 ...  -  Feb 21, 2007
Earthtimes.orgHerceptin(R), Xolair(R), Raptiva(R) and Lucentis(R) antibody products from Genentech, Inc.; Synagis(R) antibody product from MedImmune, Inc.;

XOMA to Present At Two Investor Conferences in February  -  Feb 9, 2007
PharmaLive.com (press release),XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono,

Humira takes on Amgen as treatment for psoriasis  -  Feb 8, 2007
Worcester Telegram,Results for trials of Johnson & Johnson’s Remicade and Genentech Inc.’s Raptiva were also reported at the five-day meeting that ended Tuesday.

Biotech Day in Review: Big Pharma Merger in Japan  -  Feb 4, 2007
Seeking Alpha,Genentech (DNA) reported that Raptiva was effective against psoriasis in patients with moderate-to-severe plaque psoriasis of the hands and feet.

(PRN) - Beech Street Enhances Its Healthcare Management Services ...  -  Feb 2, 2007
Bolsamania.com,...(PRN) - Genentech Announces Positive Results from a Phase IV Study of Raptiva in Patients With Moderate-to-Severe Hand and Foot Psoriasis ... [+]

Merck Serono Launches easypod(R), First Electronic Growth Hormone ...  -  Jan 30, 2007
Drug Newswire (press release),The Company has recently entered the psoriasis area with Raptiva(R). Merck Serono's research programs are focused on growing these businesses and on

Merck Serono Launches easypod(R), First Electronic Growth Hormone ...  -  Jan 29, 2007
Yahoo! News (press release)The Company has recently entered the psoriasis area with Raptiva®. Merck Serono's research programs are focused on growing these businesses and on

Zacks Analyst Blog Highlights: Xoma, Genentech, Schering-Plough ...  -  18 Jan 2007
Business Wire (press release),On January 10, 2007, Genentech (NYSE: DNA) reported sales of both Raptiva and Lucentis above expectations. Genentech pays a royalty to Xoma on sales of both

XOMA and Schering-Plough Add New Programs to Antibody Collaboration  -  18 Jan 2007
PipelineReview.com (press release),XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono,

Merck Serono Announces Positive Results From Phase III Diet Study ...  -  Jan 17, 2007
PipelineReview.com (press release),The Company has recently entered the psoriasis area with Raptiva®. Merck Serono's research programs are focused on growing these businesses and on

Merck Serono Completes Patient Enrollment in CLARITY Phase III ...  -  Jan 16, 2007
Drug Newswire (press release),The Company has recently entered the psoriasis area with Raptiva(R). Merck Serono's research programs are focused on growing these businesses and on

Genentech Announces Full Year and Fourth Quarter 2006 Results  -  Jan 10, 2007
PR Newswire (press release),275 46 Nutropin(R) products 101 95 6 378 370 2 Xolair(R) 117 93 26 425 320 33 Thrombolytics 62 58 7 243 218 11 Pulmozyme(R) 53 49 8 199 186 7 Raptiva(R)

XOMA Initiates Clinical Trial of NEUPREX At Harvard Medical School ...  -  Jan 10, 2007
PipelineReview.com (press release),XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono,

Merck Serono is Launched  -  Jan 8, 2007
Drug Newswire (press release),The Company has recently entered the psoriasis area with Raptiva(R). Merck Serono's research programs are focused on growing these businesses and on

Merck KGaA Acquires Majority Shareholding in Serono SA  -  Jan 5, 2007
Genetic Engineering News (press release),Luveris(R), Ovidrel(R )/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R). In addition to being the world leader in reproductive health,

Merck KGaA Acquires Majority Shareholding in Serono SA  -  Jan 5, 2007
Yahoo! News (press release)The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel(R )/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®.

Zacks Bull and Bear of the Day Highlights: Xoma, Frontier ...  -  Jan 5, 2007
Business Wire (press release),The company’s receives royalties on worldwide sales of psoriasis drug Raptiva and macular degeneration drug Lucentis, as well as provides contract

Genentech Q4 2006 Earnings Call Transcript  -  Jan 10, 2007
Seeking Alpha,US sales for Raptiva were $90 million 2006, a 14% increase over the prior year. Now with regard to our tissue growth and repair products, beginning with

ZymoGenetics and Serono Begin Phase 2 Clinical Trial With ...  -  Dec 19, 2006
PR Newswire (press release),The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R)/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R)

ZymoGenetics and Serono Begin Phase 2 Clinical Trial With ...  -  Dec 19, 2006
PR Newswire (press release),Luveris(R), Ovidrel(R )/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R). In addition to being the world leader in reproductive health,

ZymoGenetics and Serono Begin Phase 2 Clinical Trial With ...  -  Dec 19, 2006
PR Newswire (press release),The Company has eight biotechnology products, Rebif(R), Gonal-f(R), Luveris(R), Ovidrel(R)/Ovitrelle(R), Serostim(R), Saizen(R), Zorbtive(TM) and Raptiva(R)

Merck KGaA: European Antitrust Authorities Clear Acquisition of Serono  -  Dec 17, 2006
Yahoo! News (press release)The Company has eight biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel ®/Ovitrelle®, Serostim®, Saizen®, Zorbtive(TM) and Raptiva®.

Serono Announces Initiation Of The Reflex Trial To Evaluate New ...  -  Dec 12, 2006
PipelineReview.com (press release),Sterry et al., Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment

XOMA Announces Pre-Clinical and Clinical Progress On HCD122  -  Dec 11, 2006
PharmaLive.com (press release),XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono,

Icos starts trial of drug, opts not to disclose it  -  Dec 7, 2006
Seattle Times,Even then, he said, it will be hard to beat Raptiva, a Genentech drug that hits the same biological target. As for the mood at Icos, Gray said many

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional